Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,060,000 shares, a decrease of 28.9% from the March 31st total of 1,490,000 shares. Approximately 1.2% of the company's stock are sold short. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is currently 0.6 days.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently added to or reduced their stakes in the stock. Juncture Wealth Strategies LLC boosted its stake in Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock valued at $1,322,000 after acquiring an additional 505 shares during the last quarter. Bosun Asset Management LLC lifted its position in shares of Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock valued at $954,000 after buying an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC grew its stake in shares of Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after acquiring an additional 688 shares during the period. TD Waterhouse Canada Inc. increased its holdings in Cellebrite DI by 1.8% in the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after acquiring an additional 859 shares during the last quarter. Finally, Strategic Advisors LLC raised its stake in Cellebrite DI by 3.4% in the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after acquiring an additional 950 shares during the period. Institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on CLBT. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Lake Street Capital boosted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.43.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded down $0.33 on Monday, hitting $19.81. The stock had a trading volume of 476,583 shares, compared to its average volume of 1,417,312. Cellebrite DI has a 1 year low of $10.25 and a 1 year high of $26.30. The firm's fifty day simple moving average is $18.82 and its two-hundred day simple moving average is $20.20. The stock has a market cap of $4.74 billion, a P/E ratio of -14.25, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.